Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.72 |
| ▸ | NR4A2 | P43354 | 6/20 | 0.62 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.59 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.59 |
| ▸ | RXRA | P19793 | 5/20 | 0.58 |
| ▸ | RXRB | P28702 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | PTPRC | P08575 | 1/20 | 0.51 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30745904 | 0.86 | PTPRZ1 (0.72) | PTPRZ1NR4A2PTPN2PTPN1PTPRC | |
| SCHEMBL27927082 | 0.85 | ALDH1A1 (0.62) | PTPRZ1NR4A2RXRARXRBPTPN1 | |
| Lithium Ion SCHEMBL3275290 | 0.85 | PTPRZ1 (0.70) | PTPRZ1NR4A2NR4A1NR4A3RXRA | |
| SCHEMBL3275342 | 0.84 | PTPRZ1 (0.68) | PTPRZ1RXRARXRBNPC1POLB | |
| SCHEMBL8134318 | 0.82 | NR4A2 (0.85) | NR4A2NR4A1NR4A3RXRARXRB | |
| SCHEMBL1015553 | 0.80 | KCNK2 (0.57) | PTPRZ1SRD5A2 | |
| SCHEMBL6525591 | 0.80 | MAOB (0.76) | NR4A2NR4A1NR4A3RXRARXRB | |
| SCHEMBL22721344 | 0.80 | MRGPRX4 (0.70) | NR4A2NR4A1NR4A3RXRARXRB | |
| SCHEMBL19951231 | 0.80 | MAOB (0.76) | NR4A2NR4A1NR4A3RXRARXRB | |
| SCHEMBL30885390 | 0.77 | PTPRZ1 (0.67) | PTPRZ1NPC1RAB9ASMN1; SMN2PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756051-B1 | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI (US) | 2012-09-12 | — | — | EP | disclosed |
| US-7696234-B2 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | disclosed |
| EP-1756051-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121080-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | HRH3, HRH4, HCRTR1 | PTPRZ1 4135/4885NR4A2 736/4885NR4A1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.